StockNews.com began coverage on shares of iBio (NYSEAMERICAN:IBIO – Free Report) in a research note issued to investors on Wednesday. The firm issued a sell rating on the stock.
iBio Stock Performance
Shares of IBIO stock opened at $3.41 on Wednesday. iBio has a one year low of $1.02 and a one year high of $49.80. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04.
iBio (NYSEAMERICAN:IBIO – Get Free Report) last announced its earnings results on Friday, February 9th. The company reported ($2.42) EPS for the quarter.
iBio Company Profile
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Recommended Stories
- Five stocks we like better than iBio
- The How and Why of Investing in Biotech Stocks
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Stock Splits, Do They Really Impact Investors?
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Canadian Penny Stocks: Can They Make You Rich?
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
